Hyperfine’s QuidelOrtho Bolsters Board with Healthcare Leaders Chiminski and Huennekens

QuidelOrtho Strengthens Leadership with Key Board Appointments

QuidelOrtho Corporation, a prominent player in the in vitro diagnostic technology sector, announces the addition of two seasoned executives, John R. Chiminski and R. Scott Huennekens, to its board of directors, effective December 6, 2024. This strategic move underscores QuidelOrtho's commitment to enhancing its governance framework with leaders who have significant expertise in healthcare and diagnostics. Kenneth F. Buechler, Ph.D., the Chairman of the Board, expresses optimism about the new appointments, emphasizing that Chiminski and Huennekens bring a wealth of experience that aligns with the company's goals in the rapidly evolving diagnostic landscape.

John R. Chiminski, a former CEO of Catalent, has an impressive track record in the medical diagnostics and pharmaceuticals sectors. His leadership at Catalent included pivotal transformations, establishing the company as an independent public entity and driving significant revenue growth. Additionally, Chiminski’s tenure at GE Medical Diagnostics, where he generated $1.9 billion in sales, highlights his capability to navigate complex market dynamics and achieve substantial financial results. His proven ability to foster innovation and enhance operational efficiency positions him as a valuable asset to QuidelOrtho as it seeks to expand its footprint in the diagnostic market.

R. Scott Huennekens complements Chiminski's expertise with his extensive background in the MedTech industry. Having served as CEO of Verb Surgical—a collaboration between Google and Johnson & Johnson—Huennekens has been instrumental in launching and scaling multiple startups, bringing a robust entrepreneurial perspective to the board. Brian J. Blaser, QuidelOrtho's President and CEO, notes that the diverse insights from both new board members will be critical in shaping the company's transformational strategy and improving patient outcomes through innovative diagnostic solutions. This emphasis on leadership diversity reflects QuidelOrtho's proactive approach to navigating the complexities of the healthcare sector and driving shareholder value.

In addition to these appointments, QuidelOrtho's strategy includes leveraging the wealth of knowledge from its board members to enhance operational efficiencies and foster innovation in its product offerings. The appointments signal a concerted effort by the company to not only improve its governance but also ensure that it remains at the forefront of advancements in diagnostic technologies. As the healthcare industry continues to evolve, QuidelOrtho's focus on assembling a skilled board is a testament to its long-term vision for growth and enhanced patient care.